Given the demonstrated efficacy of ALK inhibitors, particularly second- and third-generation agents, in penetrating the blood–brain barrier and controlling CNS metastases in NSCLC, it could be hypothesized that these drugs can treat primary intracranial tumors with ALK alterations/expression, including those in the posterior cranial fossa. Here, ALK is linked to non-small cell lung carcinoma.